Company intelligence / Profile preview

Michael Camilleri

Rochester, Minnesota, USA

Ownership: Private
Employees: ~11
Development stage: Other

Overview

Phenomix Sciences commercializes the MyPhenome™ test, clinically shown to improve prediction of obesity treatment response, and is conducting prospective studies (e.g., with semaglutide) to advance precision obesity medicine.

Therapeutic areas: Endocrinology
Modalities: DiagnosticPrecision medicine testGenetic test
Industry: Molecular Diagnostics

Partnerships

Labcorp (lab testing services)

Beyond the preview

Go deeper on Michael Camilleri.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Michael Camilleri.

Explore the full profile